The aim of this pilot study was to find whether the dysregulation of neuroendocrine biomarker signaling pathways in the first episode of non-affective psychosis is a predictive factor of treatment outcome. Patients with the first episode of non-affective psychosis (N = 29) were examined at admission, at discharge, and at follow-up (N = 23). The biomarkers included serum aldosterone, cortisol, free thyroxine, thyroid stimulating hormone, and prolactin. We revealed lower baseline aldosterone and higher baseline cortisol concentrations in patients with very good outcome compared to those with good outcome after one year. We failed to reveal any significant association between treatment outcome and neurohumoral biomarkers in the whole sample at 1-year follow-up. However, baseline aldosterone concentrations negatively correlated with total PANSS scores at the discharge. Lower baseline aldosterone and higher baseline cortisol concentrations have the potential to predict a more favorable outcome for patients with the first episode of psychosis.

Department of Pharmacology and Toxicology Faculty of Pharmacy Masaryk University Brno Czech Republic

Department of Psychiatry University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Institute of Experimental Endocrinology Biomedical Research Center Slovak Academy of Sciences Bratislava Slovakia

See more in PubMed

Nucifora F.C., Jr., Woznica E., Lee B.J., Cascella N., Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol. Dis. 2019;131 doi: 10.1016/j.nbd.2018.08.016. PubMed DOI PMC

Yang A.C., Tsai S.J. New Targets for schizophrenia treatment beyond the dopamine hypothesis. Int. J. Mol. Sci. 2017;18:1689. doi: 10.3390/ijms18081689. PubMed DOI PMC

Gray J.D., Kogan J.F., Marrocco J., McEwen B.S. Genomic and epigenomic mechanisms of glucocorticoids in the brain. Nat. Rev. Endocrinol. 2017;13:661–673. doi: 10.1038/nrendo.2017.97. PubMed DOI

Borges S., Gayer-Anderson C., Mondelli V. A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology. 2013;38:603–611. doi: 10.1016/j.psyneuen.2012.12.025. PubMed DOI

Havelka D., Prikrylova-Kucerova H., Prikryl R., Ceskova E. vol. 19. 2016. pp. 383–389. (Cognitive Impairment and Cortisol Levels in First-Episode Schizophrenia Patients). Stress (Amsterdam, Netherlands) PubMed DOI

Hubbard D.B., Miller B.J. Meta-analysis of blood cortisol levels in individuals with first-episode psychosis. Psychoneuroendocrinology. 2019;104:269–275. doi: 10.1016/j.psyneuen.2019.03.014. PubMed DOI

Jezova D., Herman J.P. Stress and stress-related disease states as topics of multi-approach research. Stress. 2020;23:615–616. doi: 10.1080/10253890.2020.1853400. PubMed DOI

Joëls M., de Kloet E.R. 30 years of the mineralocorticoid receptor: the brain mineralocorticoid receptor: a saga in three episodes. J. Endocrinol. 2017;234:T49–T66. doi: 10.1530/JOE-16-0660. PubMed DOI

Hlavacova N., Jezova D. In: Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine. Harvey B., Jaisser F., editors. IntechOpen Book Series; 2019. View on aldosterone and the brain revisited; pp. 165–171. DOI

Izakova L., Hlavacova N., Segeda V., Kapsdorfer D., Morovicsova E., Jezova D. Salivary aldosterone, cortisol, and their Morning to evening slopes in patients with depressive disorder and healthy subjects: acute episode and follow-up 6 Months after reaching remission. Neuroendocrinology. 2020;110:1001–1009. doi: 10.1159/000505921. PubMed DOI

Ustohal L., Hlavacova N., Mayerova M., Ceskova E., Jezova D. Aldosterone and aldosterone/cortisol ratio is higher in serum of long-term compared to first episode schizophrenia patients: a pilot study. J. Psychiatr. Res. 2018;104:46–49. doi: 10.1016/j.jpsychires.2018.06.012. PubMed DOI

Bicikova M., Hampl R., Hill M., Ripova D., Mohr P., Putz Z. Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuroendocrinol. Lett. 2011;32:141–147. PubMed

Barbero J.D., Gutiérrez-Zotes A., Montalvo I., Creus M., Cabezas Á., Solé M., Algora M.J., Garcia-Parés G., Vilella E., Labad J. Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis. Schizophr. Res. 2015;166:37–42. doi: 10.1016/j.schres.2015.04.030. PubMed DOI

Labad J., Barbero J.D., Gutiérrez-Zotes A., Montalvo I., Creus M., Cabezas Á., Solé M., Algora M.J., Garcia-Parés G., Vilella E. Free thyroxine levels are associated with cognitive changes in individuals with a first episode of psychosis: a prospective 1-year follow-up study. Schizophr. Res. 2016;171:182–186. doi: 10.1016/j.schres.2016.01.036. PubMed DOI

Rao M.L., Gross G., Strebel B., Bräunig P., Huber G., Klosterkötter J. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res. 1990;34:243–257. doi: 10.1016/0165-1781(90)90003-n. PubMed DOI

Tost M., Monreal J.A., Armario A., Barbero J.D., Cobo J., García-Rizo C., Bioque M., Usall J., Huerta-Ramos E., Soria V., Pnecat Group, Labad J. Targeting hormones for improving cognition in major mood disorders and schizophrenia: thyroid hormones and prolactin. Clin. Drug Investig. 2020;40:1–14. doi: 10.1007/s40261-019-00854-w. PubMed DOI

Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28:53–67. doi: 10.1016/s0306-4530(02)00112-9. PubMed DOI

Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998;59:22–33. PubMed

Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261. PubMed DOI

Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry. 2003;64(6):663–667. doi: 10.4088/jcp.v64n0607. PubMed DOI

Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean? Schizophr. Res. 2005;79(2–3):231–238. doi: 10.1016/j.schres.2005.04.008. PubMed DOI

Schennach-Wolff R., Seemüller F.H., Mayr A., Maier W., Klingberg S., Heuser I., Klosterkötter J., Gastpar M., Häfner H., Sauer H., Schneider F., Gaebel W., Jäger M., Möller H.J., Riedel M. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br. J. Psychiatry. 2010;196(6):460–466. doi: 10.1192/bjp.bp.109.069328. PubMed DOI

Schennach-Wolff R., Jäger M., Mayr A., Meyer S., Kühn K.U., Klingberg S., Heuser I., Klosterkötter J., Gastpar M., Schmitt A., Schlösser R., Schneider F., Gaebel W., Seemüller F., Möller H.J., Riedel M. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? Eur. Neuropsychopharmacol. 2011;21:370–378. doi: 10.1016/j.euroneuro.2010.10.003. PubMed DOI

Andreasen N.C., Carpenter W.T., Jr., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry. 2005;162:441–449. doi: 10.1176/appi.ajp.162.3.441. PubMed DOI

Allott K.A., Yuen H.P., Bartholomeusz C.F., Rapado-Castro M., Phassouliotis C., Butselaar F., Wood S.J., Proffitt T.M., Savage G., Phillips L.J., Bendall S., Markulev C., Reniers R.L.E.P., Pantelis C., Baldwin L., McGorry P.D., Garner B. Stress hormones and verbal memory in young people over the first 12 weeks of treatment for psychosis. Psychiatry Res. 2018;260:60–66. doi: 10.1016/j.psychres.2017.11.044. PubMed DOI

Mondelli V., Ciufolini S., Belvederi Murri M., Bonaccorso S., Di Forti M., Giordano A., Marques T.R., Zunszain P.A., Morgan C., Murray R.M., Pariante C.M., Dazzan P. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis, schizophr. Bull. (Arch. Am. Art) 2015;41:1162–1170. doi: 10.1093/schbul/sbv028. PubMed DOI PMC

Jezová-Repceková D., Klimes I., Jurcovicová J., Vigas M. Effect of adrenergic receptor blockade on cortisol and GH response to insulin-induced hypoglycemia in man. Int. J. Clin. Pharmacol. Biopharm. 1979;17(2):64–67. PubMed

Cohrs S., Röher C., Jordan W., Meier A., Huether G., Wuttke W., Rüther E., Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology. 2006;185(1):11–18. doi: 10.1007/s00213-005-0279-x. PubMed DOI

David S.R., Taylor C.C., Kinon B.J., Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. 2000;22:1085–1096. doi: 10.1016/S0149-2918(00)80086-7. PubMed DOI

Jezova D., Makatsori A., Duncko R., Moncek F., Jakubek M. High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2004;28:1331–1336. doi: 10.1016/j.pnpbp.2004.08.005. PubMed DOI

Bunevicius R., Steibliene V., Prange A.J., Jr. Thyroid axis function after in-patient treatment of acute psychosis with antipsychotics: a naturalistic study. BMC Psychiatr. 2014;14:279. doi: 10.1186/s12888-014-0279-7. PubMed DOI PMC

Schimmelmann B.G., Mehler-Wex C., Lambert M., Schulze-zur-Wiesch C., Koch E., Flechtner H.H., Gierow B., Maier J., Meyer E., Schulte-Markwort M. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. Child. Adolesc. Psychopharmacol. 2007;17(6):768–778. doi: 10.1089/cap.2007.0048. PubMed DOI

Fraguas D., Merchán-Naranjo J., Laita P., Parellada M., Moreno D., Ruiz-Sancho A., Cifuentes A., Giráldez M., Arango C. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J. Clin. Psychiatry. 2008;69(7):1166–1175. doi: 10.4088/jcp.v69n0717. PubMed DOI